Introduction
Gastric intestinal metaplasia (GIM) is a recognised precursor to gastric adenocarcinoma, yet international surveillance recommendations remain heterogeneous, creating clinical uncertainty and disparities in cancer prevention¹. While recent reviews have catalogued guideline discordance, none have proposed a structured implementation pathway or evaluated the emerging role of metabolic risk factors.
Aims & Methods
This review synthesises current international guidance, quantifies domains of consensus and discordance, and proposes a tiered harmonisation framework integrating metabolic risk stratification. A comparative analysis was performed across seven guideline documents from the American Gastroenterological Association (AGA, 2020 and 2025)², American College of Gastroenterology (ACG), European Society of Gastrointestinal Endoscopy (ESGE), British Society of Gastroenterology (BSG), and Asian-Pacific consensus statements including the 2026 Asian Pacific Association of Gastroenterology Task Force recommendations³. Eight domains were evaluated: risk stratification, surveillance indications and intervals, Operative Link on Gastritis/Intestinal Metaplasia Assessment (OLGA/OLGIM) staging, image-enhanced endoscopy, biopsy protocols, non-invasive biomarkers, discontinuation criteria, and metabolic risk factor incorporation.
Results
Consensus was identified in 3 of 8 domains: universal Helicobacter pylori eradication, surveillance avoidance for isolated low-risk antral GIM, and recognition of high-risk features (corpus-extended involvement, incomplete histological subtype, OLGIM III/IV, family history of gastric cancer)¹.
Discordance was identified in 5 of 8 domains. Surveillance intervals ranged from 1 to 5 years. United States guidance emphasises individualised shared decision-making², whereas European and Asian-Pacific recommendations support structured surveillance for higher-risk individuals³. OLGIM staging adoption, image-enhanced endoscopy, and Sydney protocol adherence varied substantially. Discontinuation criteria and pepsinogen-based biomarkers remain inadequately addressed.
No guideline formally incorporates metabolic risk factors, despite evidence that obesity independently increases GIM incidence in a dose-response manner⁴, diabetes mellitus predicts GIM persistence and progression to dysplasia (odds ratio 2.54)⁵, and metabolic syndrome is associated with 26–44% increased gastric cancer risk⁶.
A tiered harmonisation pathway is proposed: (1) immediate standardisation — H. pylori eradication, low-risk GIM non-surveillance, family history incorporation; (2) implementation priorities — OLGIM staging, Sydney protocol biopsy mapping, image-enhanced endoscopy; (3) prospective evidence needed — optimal intervals, discontinuation criteria, biomarker integration, and metabolic risk factor incorporation.
Conclusion
This analysis identifies actionable harmonisation targets across international GIM surveillance guidelines and proposes a tiered framework integrating metabolic risk perspectives aligned with European initiatives including Gastric Cancer Prevention by Helicobacter pylori Treatment and Surveillance in a Randomised Trial (GISTAR) and European Cancer Screening (EUCanScreen)¹. Adoption could reduce practice variation and advance equitable gastric cancer prevention.
References
1. Dinis-Ribeiro M, Shah S, El-Serag H, et al. The road to a world-unified approach to the management of patients with gastric intestinal metaplasia. Gut. 2024;73(10):1607-1617.
2. Shah SC, Wang AY, Wallace MB, Hwang JH. AGA Clinical Practice Update on screening and surveillance in individuals at increased risk for gastric cancer. Gastroenterology. 2025;168(2):405-416.
3. Leung WK, Ang TL, Shah S, et al. Asian Pacific Association of Gastroenterology Task Force recommendations on surveillance for gastric premalignant conditions. Gut. 2026;75(4):685-704.
4. Kim K, Chang Y, Ahn J, et al. Body mass index and risk of intestinal metaplasia: a cohort study. Cancer Epidemiol Biomarkers Prev. 2019;28(4):789-797.
5. Aumpan N, Vilaichone RK, Pornthisarn B, et al. Predictors for regression and progression of intestinal metaplasia. PLoS One. 2021;16(8):e0255601.
6. Huang D, Shin WK, De la Torre K, et al. Association between metabolic syndrome and gastric cancer risk. Gastric Cancer. 2023;26(4):481-492.
Disclosure
None